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SI/CTR Abstract 
 
Nighttime Melatonin Administration and Insulin Sensitivity 
Albert McHugh BA, Cynthia Cheng MD, PhD* 
 
Introduction: Previous studies have shown melatonin effects on insulin sensitivity, but 
with conflicting results. The inconsistency between these studies may be due to 
differences in melatonin dosage and subject age.  Low melatonin dosages, generally <5 
mg, have been used in prior research. We studied the effect of melatonin 9 mg for 6 
weeks on insulin resistance, peripheral microvascular function, and sleep in non-
diabetic, non-hypertensive middle-aged and geriatric patients. 
Methods: Subjects with a history of hypertension or diabetes were excluded from the 
study. The geriatric cohort included 5 subjects 60-80 years old while the younger cohort 
was comprised of 14 subjects age 27-45 years old. Fifteen subjects were randomized to 
the melatonin treatment group and took 9 mg of controlled-release melatonin by mouth 
30 minutes before bedtime for 6 weeks; the four subjects in the control did not receive 
any intervention. The Homeostatic Model Assessment (HOMA) and the Quantitative 
Insulin-Sensitivity Check Index (QUICKI) were used to assess insulin sensitivity. 
Results: We observed a statistically significant increase in insulin sensitivity in the 
melatonin treatment group (p=.008) compared to the control group after HOMA 
analysis.  Additionally, fasting insulin levels also improved within the melatonin 
treatment group. We did not see any significant changes in glucose levels after 
melatonin usage. 
Discussion: The findings are limited by the small size of this pilot study. However, 
given these promising results, we are applying for funding to study a larger number of 
subjects to further examine age-related differences in insulin and glucose metabolism in 
response to melatonin usage. 
 
